He YL, et al. - In patients with type-2 diabetes-mellitus (T2DM) and/or obesity, researchers evaluated the effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter (SGLT) 1/2, on body weight, metabolic parameters and incretin hormones. In patients with obesity, licogliflozin 150 mg QD for 12 weeks significantly reduced body-weight by 5.7% vs placebo and improved metabolic parameters like significantly reduced postprandial glucose excursion, reduced insulin levels, and increased glucagon. An attractive strategy to treat obesity and diabetes is the dual inhibition of SGLT1/2 with lycogliflozin in the gut and kidneys.